Australia TGA
Material regulatory developments from Therapeutic Goods Administration are tracked daily by Cresthaven Analytics. Over the last 90 days, 20 material briefs relevant to professionals operating in the healthcare & life sciences sector have been published below. Each brief is sourced directly from the primary regulatory feed, summarized for institutional readers, and scored for materiality.
Recent material activity
-
TGA mandates class-wide product warning updates for GLP-1 receptor agonists over rare severe vision disorder risk
Australia's Therapeutic Goods Administration issued a safety update on July 23, 2026 requiring product warning updates across the entire glucagon-like-peptide-1 receptor agonist class. The update reflects a determination…
Read a full sample brief → -
TGA publishes June 2026 Product Information safety updates across multiple medicine classes
Australia's Therapeutic Goods Administration has published its June 2026 compilation of safety-related Product Information updates for health professionals. The release consolidates labelling and prescribing information …
Read a full sample brief → -
TGA conducts multi-agency enforcement operation against illegal nicotine products at three Darwin premises
On July 9, 2026, the Therapeutic Goods Administration executed a targeted enforcement operation across three Darwin premises, working alongside NT Health, the Northern Territory Police Force, and the Northern Territory D…
Read a full sample brief → -
TGA publishes guidance on section 9D(1) correction applications for listed medicines on the ARTG
The Therapeutic Goods Administration released a new information page on July 16, 2026 addressing the section 9D(1) correction mechanism for listed medicines. The guidance clarifies when sponsors may apply to correct info…
Read a full sample brief → -
TGA issues five infringement notices totalling $99,000 to Acacia Pharmacy for unlawful melatonin imports
Australia's Therapeutic Goods Administration issued five infringement notices to Acacia Pharmacy Pty Ltd on or before July 15, 2026. The notices total $99,000 and allege unlawful importation of unapproved melatonin produ…
Read a full sample brief → -
TGA issues three infringement notices totalling $59,400 to Queensland vaping goods supplier for non-compliance with information request
The Therapeutic Goods Administration issued three infringement notices totalling $59,400 to Queensland-based Canngea Pty Ltd in March 2026, alleging failure to comply with a statutory request for information about the su…
Read a full sample brief → -
TGA issues safety update linking Ashwagandha herbal preparations to ongoing liver injury reports in Australia and internationally
The Therapeutic Goods Administration issued a safety update on July 7, 2026 addressing continued reports of liver injury associated with herbal preparations containing Withania somnifera. The signal remains unresolved. I…
Read a full sample brief → -
TGA issues three infringement notices to a nurse for unlawful importation of unapproved cosmetic injectables
Australia's Therapeutic Goods Administration issued three infringement notices totalling AUD 11,880 to a nurse on July 6, 2026, for alleged unlawful importation of unapproved cosmetic injectables under the Therapeutic Go…
Read a full sample brief → -
TGA activates mandatory Unique Device Identification requirements for specified medical devices effective 1 July 2026
Australia's Therapeutic Goods Administration published a notice on 30 June 2026 confirming that mandatory Unique Device Identification requirements for specified medical devices take effect 1 July 2026. The requirements …
Read a full sample brief → -
Australian health regulators issue joint public health warning on unapproved peptide products amid growing availability concerns
Australia's Therapeutic Goods Administration and allied health leaders issued a joint statement on June 19, 2026 addressing the growing availability, promotion, and use of unapproved peptide products. The statement signa…
Read a full sample brief → -
TGA issues updated compliance guidance on advertising restrictions for prescription medicines in Australia
On June 17, 2026, Australia's Therapeutic Goods Administration published new guidance on advertising restrictions for prescription medicines. The guidance is directed at individuals and businesses to support compliance w…
Read a full sample brief → -
TGA issues five infringement notices totalling $19,800 for unlawful importation of unapproved cosmetic injectables
Australia's Therapeutic Goods Administration issued five infringement notices on June 17, 2026 against a health practitioner and an individual for alleged unlawful importation of unapproved cosmetic injectables. This act…
Read a full sample brief → -
TGA publishes May 2026 batch of safety-driven Product Information updates for health professionals
Australia's Therapeutic Goods Administration published its May 2026 compilation of safety-related Product Information updates on June 15, 2026. The release consolidates label and prescribing-information amendments across…
Read a full sample brief → -
TGA designates unapproved peptide products a priority compliance focus area amid rising unlawful importation and supply
Australia's Therapeutic Goods Administration (TGA) expanded its priority compliance focus areas on June 10, 2026 to include unapproved peptide products. The designation follows increased detection of unlawful importation…
Read a full sample brief → -
TGA issues safety alert on FluMist age-range administration errors in children under 2 years
Australia's Therapeutic Goods Administration issued a safety alert on June 5, 2026 identifying reports of FluMist being administered in error to children under 2 years of age. FluMist is not indicated for that age group.…
Read a full sample brief → -
TGA issues 27 infringement notices totalling $101,412 against NSW individual for unlawful Melanotan II supply
The Therapeutic Goods Administration issued 27 infringement notices on or before May 21, 2026, totalling $101,412, against a NSW-based individual. The notices allege unlawful supply of Melanotan II to Australian consumer…
Read a full sample brief → -
Australia TGA release pending Cresthaven Analytics full analysis: Unlawful therapeutic goods seized in global operation
Australia TGA published a regulatory release titled 'Unlawful therapeutic goods seized in global operation'. Cresthaven Analytics' full intelligence brief is pending re-analysis; see the source link below for the complet…
Read a full sample brief → -
TGA issues safety alert on tranexamic acid spinal administration errors linked to deaths internationally
Australia's Therapeutic Goods Administration published a safety update on May 18, 2026 identifying internationally reported medication errors involving inadvertent intrathecal administration of tranexamic acid injection.…
Read a full sample brief → -
TGA publishes consolidated compliance guidance for compounded medicine manufacturing, supply, and advertising
Australia's Therapeutic Goods Administration published updated guidance titled 'Manufacturing, supplying and advertising compounded medicines lawfully' on May 13, 2026. The guidance consolidates compliance requirements a…
Read a full sample brief → -
Australia's TGA alerts exporters to Indonesia's emerging halal certification requirements for medicines and medical devices
Australia's Therapeutic Goods Administration published a notice on May 13, 2026 alerting sponsors and manufacturers to new halal certification requirements under Indonesia's Halal Product Assurance (Jaminan Produk Halal)…
Read a full sample brief →
Get every Australia TGA brief delivered the day it lands
From $149/month
Cresthaven Analytics monitors Therapeutic Goods Administration continuously, applying institutional materiality scoring to every release. Subscribers receive structured briefs via email, portal, and (Executive tier and above) real-time alerts.
View all tiers →